» Articles » PMID: 30287940

Humanization of Antibodies Using a Statistical Inference Approach

Overview
Journal Sci Rep
Specialty Science
Date 2018 Oct 6
PMID 30287940
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Antibody humanization is a key step in the preclinical phase of the development of therapeutic antibodies, originally developed and tested in non-human models (most typically, in mouse). The standard technique of Complementarity-Determining Regions (CDR) grafting into human Framework Regions of germline sequences has some important drawbacks, in that the resulting sequences often need further back-mutations to ensure functionality and/or stability. Here we propose a new method to characterize the statistical distribution of the sequences of the variable regions of human antibodies, that takes into account phenotypical correlations between pairs of residues, both within and between chains. We define a "humanness score" of a sequence, comparing its performance in distinguishing human from murine sequences, with that of some alternative scores in the literature. We also compare the score with the experimental immunogenicity of clinically used antibodies. Finally, we use the humanness score as an optimization function and perform a search in the sequence space, starting from different murine sequences and keeping the CDR regions unchanged. Our results show that our humanness score outperforms other methods in sequence classification, and the optimization protocol is able to generate humanized sequences that are recognized as human by standard homology modelling tools.

Citing Articles

50 Years of Antibody Numbering Schemes: A Statistical and Structural Evaluation Reveals Key Differences and Limitations.

Zhu Z, Olson K, Magliery T Antibodies (Basel). 2024; 13(4).

PMID: 39727482 PMC: 11672675. DOI: 10.3390/antib13040099.


abnization platform: A monoclonal antibody heterologization server based on rational design and artificial intelligence-assisted computation.

Hao X, Liu D, Fan L Comput Struct Biotechnol J. 2024; 23:3222-3231.

PMID: 39660217 PMC: 11630649. DOI: 10.1016/j.csbj.2024.08.013.


Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics.

Carter P, Quarmby V Nat Rev Drug Discov. 2024; 23(12):898-913.

PMID: 39424922 DOI: 10.1038/s41573-024-01051-x.


Prospects for the computational humanization of antibodies and nanobodies.

Gordon G, Raybould M, Wong A, Deane C Front Immunol. 2024; 15():1399438.

PMID: 38812514 PMC: 11133524. DOI: 10.3389/fimmu.2024.1399438.


The rise of big data: deep sequencing-driven computational methods are transforming the landscape of synthetic antibody design.

Gallo E J Biomed Sci. 2024; 31(1):29.

PMID: 38491519 PMC: 10943851. DOI: 10.1186/s12929-024-01018-5.


References
1.
Baldassi C, Zamparo M, Feinauer C, Procaccini A, Zecchina R, Weigt M . Fast and accurate multivariate Gaussian modeling of protein families: predicting residue contacts and protein-interaction partners. PLoS One. 2014; 9(3):e92721. PMC: 3963956. DOI: 10.1371/journal.pone.0092721. View

2.
Chailyan A, Tramontano A, Marcatili P . A database of immunoglobulins with integrated tools: DIGIT. Nucleic Acids Res. 2011; 40(Database issue):D1230-4. PMC: 3245095. DOI: 10.1093/nar/gkr806. View

3.
Gabbard J, Velappan N, Di Niro R, Schmidt J, Jones C, Tompkins S . A humanized anti-M2 scFv shows protective in vitro activity against influenza. Protein Eng Des Sel. 2008; 22(3):189-98. DOI: 10.1093/protein/gzn070. View

4.
Harding F, Stickler M, Razo J, DuBridge R . The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010; 2(3):256-65. PMC: 2881252. DOI: 10.4161/mabs.2.3.11641. View

5.
Abhinandan K, Martin A . Analyzing the "degree of humanness" of antibody sequences. J Mol Biol. 2007; 369(3):852-62. DOI: 10.1016/j.jmb.2007.02.100. View